Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Vor Biopharma Inc VOR

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development... see more

Recent & Breaking News (NDAQ:VOR)

Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs

GlobeNewswire June 17, 2021

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

GlobeNewswire June 11, 2021

Vor to Develop Multi-Targeted CAR-Ts with Abound Bio

GlobeNewswire June 10, 2021

Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences

GlobeNewswire May 25, 2021

Vor Reports First Quarter 2021 Financial Results and Provides Company Update

GlobeNewswire May 6, 2021

Vor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT

GlobeNewswire April 28, 2021

Vor Reports Fiscal Year 2020 Financial Results

GlobeNewswire March 25, 2021

Vor Biopharma to Present at the Barclays Global Healthcare Conference

GlobeNewswire March 5, 2021

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

GlobeNewswire March 1, 2021

Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares

GlobeNewswire February 9, 2021

PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering

Business Wire February 5, 2021

Vor Biopharma Announces Pricing of Initial Public Offering

GlobeNewswire February 5, 2021